Tauriga Launches CBD Infused Tauri-Gum™


Company News

Welcome To Tauriga Sciences

Tauriga Sciences would like to thank all its loyal shareholders as well as welcome new shareholders. Management believes 2021 has the potential to be an exciting year for the Company.  Over the course of the past two years, Management has been working diligently to both restore and create shareholder value for the Company’s shareholders.


The Company has previously indicated in press releases and SEC Filings, its intent to pursue a major potential acquisition(s) and or product development initiative(s).   Over the past year, the Company has also been contemplating opportunities involving product development and commercialization initiative(s).







Tauriga Sciences Inc. (“Tauriga”), through a contract manufacturing agreement with Maryland based Per Os BioSciences LLC, has developed a CBD Infused Chewing Gum Product Line (“CBD Gum”), branded under the name: Tauri-GumTM.  This CBD Gum has been manufactured via a patented process (as expressed by U.S. Patent # 9,744,128 – wholly owned by the manufacturer) and is distributed exclusively by Tauriga.  The CBD Gum is Gluten-Free, Non-GMO, Allergen-Free, Vegan, Kosher (formally certified as Kosher on January 29, 2019 by Star-K), and Pareve (non-dairy).  The initial production run is being completed exclusively in Mint flavor and the product is only being sold to individuals of age 18 and older.  This is a high quality product, 3rd party tested (for Quality Assurance), and drug test safe. The Company officially launched  Tauri-Gum TM on March 11th, 2019 and has a dedicated E-Commerce site under the URL Address: www.taurigum.com.


The Company has announced that both individual packs and retail display boxes of will be for sale.  The individual pack contains 8 large gum chewing gum tablets (each containing 10mg of CBD Isolate).  The retail display box (“retail box”) contains 10 individual packs.
The Company has been assigned distinct GS1 Barcodes for both the individual pack as well as the retail box.  The Company expects to sell each individual pack for $17.99 and each retail box for $179.99.  There will be no shipping fees assessed for orders of 2 or more individual packs or one or more retail boxes.


One such opportunity on which the Company has acted (initially disclosed during December 2018), involves the Company entering into the cannabidiol (or “CBD”) infused chewing gum product business for retail customers and as a pharmaceutical gum for relieving nausea symptoms for chemotherapy patients. These opportunities are  more fully described above and in prior press releases. This CBD infused chewing gum product has been branded under the following name: Tauri-Gum™. See also our periodic reports filed by us with the SEC for a more complete description of our business and material agreements that we have entered into.  The Company now has developed 5 proprietary CBD gum flavors including;


  •        Pomegranate (10 mg CBD)
  •        Blood Orange (10 mg CBD)
  •        Lemon Peach (10 mg CBG)
  •        Mint (10 mg CBD)
  •        Black Currant (15 mg CBG)


The Company also developed an immune booster Pear Bellini flavored chewing gum containing 60mg of Vitamin C and 10 mg of Zinc.


Shop Now At taurigum.com


Equity Investments

The Company currently has equity stakes in three exciting growth companies. As previously stated, the Company holds an equity position in privately held Aegea Biotechnologies. The Company also holds an equity stake in Serendipity Brands, one of the fastest-growing ice cream company that is now sold in nearly 30,000 stores.  The Company has long held a large position in Vista Gen Therapeutics, a biotech company with several developing drugs in the depression and social anxiety space.

Learn More


Nausea Therapy

Based on feedback and testimonials from Tauri-Gum™ customers, the Company developed a proprietary stronger gum formulation consisting of nutriceuticals including CBD for aiding patients with nausea symptoms primarily caused by chemotherapy. The Company retained and has filed a provisional patent for its formulation and is currently working with the FDA in preparation for clinical trials.  The nausea relief market is estimated to be  $7 billion dollars annually.

Learn More


COVID Testing - Aegea

The Company is also working on a collaboration with  Aegea Biotechnologies to develop next-generation virus tests including for COVID-19. The Company also has an equity stake in Aegea Biotechnologies.  Aegea Biotechnologiescurrently holds 11 issued US patents including its Switch Blocker and Primer Switch patents that are currently generating revenue in the oncology liquid biopsy space.

Learn More!


Star-K Kosher Certification

Formally certified as Kosher on January 29, 2019 by Star-K

Click Here to download PDF


Recent Press Releases

Fully committed to commercializing innovation to enhance personal wellness, improve our environment and create lasting shareholder value.